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Summary
Erk/MAPK and TGFb signaling cause epithelial tomesenchymal transition (EMT) andmetastasis inmousemammary epithe-
lial cells (EpH4) transformedwith oncogenic Ras (EpRas). In trials to unravel underlyingmechanisms, expression profiling for
EMT-specific genes identified a secreted interleukin-related protein (ILEI), upregulated exclusively at the translational level.
Stable overexpression of ILEI in EpH4 and EpRas cells caused EMT, tumor growth, and metastasis, independent of TGFb-R
signaling and enhanced by Bcl2. RNAi-mediated knockdown of ILEI in EpRas cells before and after EMT (EpRasXT) pre-
vented and reverted TGFb-dependent EMT, also abrogating metastasis formation. ILEI is overexpressed and/or altered in
intracellular localization in multiple human tumors, an event strongly correlated to invasion/EMT, metastasis formation,
and survival in human colon and breast cancer.Introduction
During generation, progression, and metastasis of epithelial
tumors (carcinomas), oncogenes and tumor suppressor genes
cause multiple cell-autonomous alterations, e.g., aberrant con-
trol of proliferation, apoptosis, angiogenesis, and cellular life
span (Hahn and Weinberg, 2002). Particularly during late-stage
carcinoma progression, crosstalk between the often heteroge-
neous tumor cells and different cell types of the ‘‘tumor stroma’’
is essential (for review, see Mueller and Fusenig, 2004). Besides
cell-cell interactions and interaction with the (often modified)
extracellular matrix (ECM), this crosstalk involves multiple se-
creted proteins acting in an autocrine or paracrine fashion
(e.g., chemokines, cytokines, tyrosine/serine kinase ligands, de-
velopmental regulators; Balkwill, 2004; Coussens and Werb,
2002). Epithelial-mesenchymal transition (EMT), a process gov-
erned by these heterotypic cell interactions, has emerged as
a central process during embryonic development, cancer pro-
gression, metastasis, and chronic inflammation/fibrosis (Balk-
will, 2004; Huber et al., 2005; Thiery, 2003).CANCER CELL 10, 227–239, SEPTEMBER 2006 ª2006 ELSEVIER INC. DOEMT has been intensely studied in tissue culture models of
epithelial cells—including nontumorigenic, polarized mammary
gland epithelial cells (EpH4; Gru¨nert et al., 2003; Janda et al.,
2002a)—and transgenic mouse tumor models (Siegel et al.,
2003). EpH4 cells transformed with oncogenic Ras (EpRas)
are tumorigenic. Both in vitro and in mice, EpRas cells undergo
EMT in response to TGFb, stabilized by an autocrine TGFb loop
(Oft et al., 1996). Also, in other cellular models, sustained TGFbR
signaling maintains EMT and is important for metastasis in vivo
(Oft et al., 1998; Yang et al., 2002).
EpRas cells fail to metastasize from primary tumors but read-
ily do so upon tail vein injection (Jechlinger et al., 2006), thus be-
ing able to perform late steps in metastasis. Using EpH4 cells
expressing Ras effector mutants, we showed that Ras-depen-
dent MAPK pathway hyperactivation is required for both EMT
and metastasis (EpS35 cells). In contrast, a Ras-induced, hy-
peractive PI3K pathway caused reversible ‘‘scattering’’ but not
EMT and was essential for apoptosis protection and acceler-
ated tumor growth (EpC40 cells; Janda et al., 2002a, 2002b).
Besides the Ras-TGFb cooperation, numerous other signalingS I G N I F I C A N C E
Metastatic progression of carcinomas causes >80% of cancer deaths and involves crosstalk of carcinoma cells with multiple other cell
types, frequently involving secreted cytokines/chemokines often overlooked in expression profiling studies due to exclusive transla-
tional control. Expression profiling of polysome bound mRNA identified ILEI, a cytokine-like protein both necessary and sufficient for
EMT, tumorigenesis, and metastasis of normal epithelial cells. Discovery of ILEI thus added a key player to the growing list of mecha-
nisms governingmetastasis. Abnormal ILEI expression (cytoplasmic overexpression instead of vesicular localization) was clearly asso-
ciatedwith EMT in human colon cancer and predictive for metastasis formation and poor prognosis in human breast cancer, rendering
ILEI a promising target for therapeutic intervention by humanized monoclonal antibodies.I 10.1016/j.ccr.2006.07.020 227
A R T I C L EFigure 1. ILEI: Identification, immunodetection,
and expression analysis in cells
A: Polysome bound mRNA expression profiling
data showing that ILEI is upregulated (red nu-
merals; Jechlinger et al., 2003) in EMT cell pairs
undergoing EMT and tumor and metastasis for-
mation (+), but not (black numerals) in nonmeta-
static scattering (sc.) cell pairs without (2) or with
(+) tumor formation. For details, see cartoons
and Supplemental Experimental Procedures.
B: EpRas and EpRasXT cells were analyzed for to-
tal and polysome bound (psb) mRNA levels by
semiquantitative RT-PCR, using b-actin as load-
ing control. Representative data from one out
of five experiments with similar results are shown.
C: Affinity-purified anti-ILEI peptide antibodies
(see Experimental Procedures) detect both V5-
tagged (Cos-ILEI-tag) and native exogenous
ILEI (Cos ILEI native) in Cos cells transfected with
respective expression vectors by Western blot
analysis or endogenous ILEI in EpH4 cells. Speci-
ficity is shown by peptide block employing the
ILEI peptide used for immunization. Positive con-
trol, anti-V5 antibodies; negative control, mock-
transfected Cos cells.
D: Secreted ILEI protein from the cell pairs shown
inA was analyzed in concentrated supernatants
(Experimental Procedures) by Western blot. Rep-
resentative data from one out of three experi-
ments with identical results are shown.pathways (e.g., hedgehog, Notch, and wnt/b-catenin signaling)
and transcriptional regulators (e.g., Twist, NFkB, STAT3, Id2/3,
and particularly the Snail superfamily) contribute to EMT in de-
velopment and cancer (for review, see Huber et al., 2005).
One possible reason why so many different, often crosstalk-
ing mechanisms cause EMT is that the term ‘‘EMT’’ comprises
a wide spectrum of changes in epithelial plasticity. These can
be reversible or metastable and may involve less or more severe
gene expression changes toward a mesenchymal cell pheno-
type (reviewed in Gru¨nert et al., 2003; Huber et al., 2005). ‘‘Com-
plete EMT’’—defined by a metastable, fibroblastoid phenotype
plus loss of E-cadherin and gain of vimentin (Janda et al.,
2002a)—was most closely correlated with local invasion and
metastasis (Gru¨nert et al., 2003). In an attempt to molecularly
characterize this ‘‘complete EMT’’ phenotype, EpH4- and
CT26-derived cell pairs showing scattering or complete EMT
(Figure 1A; see the Supplemental Experimental Procedures in
the Supplemental Data available with this article online) were
employed for expression profiling of polysome bound mRNA,
allowing additional detection of translationally regulated genes
(Pradet-Balade et al., 2001; Jechlinger et al., 2003). A cluster
of >30 genes specific for ‘‘complete EMT’’ and metastasis
was identified, which served to identified a translationally regu-
lated gene that belongs to a recently discovered gene family228(FAM3A–D) with no sequence homology to known genes (Zhu
et al., 2002). We show here that the FAM3C protein, referred
to as interleukin-like EMT inducer (ILEI), is both necessary and
sufficient to cause EMT, slow tumor growth, and late steps in
metastasis. ILEI was also shown to be an important player in
human cancer progression.
Results
ILEI mRNA translation and protein secretion
is specifically upregulated during EMT
Polysome bound mRNA expression profiling of four EpH4-
derived cell pairs undergoing complete EMT or scattering—and
the colon carcinoma-derived EMT cell pair CKR2-CT26—
revealed EMT/metastasis-specific ILEI expression (Figure 1A
and Supplemental Experimental Procedures). Semiquantitative
RT-PCR for ILEI showed that polysome bound but not total
ILEI mRNA was strongly upregulated in mesenchymal EpRasXT
cells as compared to epithelial EpRas cells (Figure 1B), clearly
showing translational control of ILEI expression.
To verify these findings at the protein level, we raised and
affinity purified peptide antibodies to ILEI in rabbits (see Ex-
perimental Procedures). One of these antibodies identified
V5-tagged and untagged ILEI protein in Western blots afterCANCER CELL SEPTEMBER 2006
A R T I C L Eexogenous expression in COS cells, as well as endogenous ILEI
expressed in EpH4 cells (Figure 1C, specificity shown by pep-
tide block). More importantly, analysis of supernatants from
cell pairs undergoing or not undergoing EMT (Figure 1A; Jechlin-
ger et al., 2003) showed that secreted—but not total—ILEI pro-
tein was upregulated in cell pairs undergoing EMT, but not in
those undergoing scattering (Figure 1D and data not shown;
see Discussion).
Expression of exogenous ILEI induces EMT in normal
and transformed epithelial cells
To determine if ILEI alters epithelial plasticity, EpH4 cells and
their various derivatives were infected with a ILEI-IRES-GFP ret-
roviral vector and sorted for strongly GFP-positive cell popula-
tions (see Experimental Procedures). Western blot analysis of
these cell populations using anti-ILEI antibodies showed that
all EpH4/EpRas derivatives infected with the ILEI retrovirus
showed the expected enhanced expression of secreted ILEI
(Figure 2C, top panels).
Efficient EMT induction in the EpRas model strongly depends
on culture conditions (plastic dishes, porous supports, or colla-
gen gels; Gru¨nert et al., 2003). This prompted us to analyze both
ILEI-expressing cells and GFP retrovirus-infected control cells
under these different conditions for morphology, motility, and
expression of epithelial and mesenchymal markers. Both on
plastic and in collagen gels, ILEI expression either did not affect
or slightly reduced proliferation of these cells (Figure S1D and
data not shown).
In collagen gels, all EpH4-derived cells expressing ILEI under-
went complete EMT, forming unordered structures of fibroblas-
toid cells expressing vimentin but not E-cadherin (Figure 2A,
Figures S1B and S1C), a phenotype that was stable during en-
largement of the cell structures. On porous supports (still sup-
porting complete epithelial polarity), ILEI induced complete
EMT—persisting in confluent cultures—in EpRas and EpS35
cells, which undergo EMT in response to TGFb and a hyperactive
Erk/MAPK pathway (EpRas, EpS35). In contrast, EpH4-ILEI,
EpBcl-2-ILEI, and EpC40-ILEI cells on filters underwent EMT
in sparse cultures, which was reversed in confluent monolayers
(Figure S1A), possibly due to blocked passage of apically se-
creted ILEI through the filter pores to reach the presumably ba-
solateral ILEI receptors. Similarly, sparse cultures on plastic of
ILEI-expressing EpH4, EpBcl-2, and EpC40 cells showed a fi-
broblastoid phenotype and EMT, which reverted to an epithelial
phenotype in larger epithelial islands or cell sheets (Figure 2A
and Figures S1A and S1B). In contrast, ILEI induced complete
EMT at all cell densities in EpRas and EpS35 cells cultivated
on plastic (see Discussion).
The above results on marker expression could be confirmed
by Western blot analysis (Figure 2C), showing that EpRas-ILEI
and EpS35-ILEI completely lost E-cadherin expression and
gained vimentin expression while EpH4-ILEI, EpBcl-2-ILEI,
and EpC40-ILEI cells (harvested from semiconfluent cultures)
showed only partial phenotypes with respect to epithelial/mes-
enchymal marker expression. In conclusion, stable expression
of ILEI induces EMT in all EpH4 derivatives in collagen gels
but requires a hyperactive Erk/MAPK pathway for EMT on plas-
tic (Figure S1B).
Since TGFb-induced EMT in EpRas cells depends on an ele-
vated Erk/MAPK pathway induced by oncogenic Ras, we tested
whether stable ILEI expression had similar effects. In both EpH4CANCER CELL SEPTEMBER 2006and EpC40 cells, which show basal Erk/MAPK activation, ILEI
expression enhanced phospho-Erk levels (Figure 2C). Further-
more, a nontoxic Ras farnesylation inhibitor (L739.749; Janda
et al., 2002a) reverted EMT in EpH4-ILEI and EpC40 ILEI cells
(Figure 2F), suggesting that Ras function is important in ILEI-
induced EMT. Finally, we tested whether stable ILEI expression
would induce cell migration, employing in vitro wound healing
assays. Indeed, EpH4-ILEI and EpC40-ILEI cells closed a
‘‘wound’’ scratched into a confluent epithelial monolayer much
faster than respective control cells expressing the empty GFP
vector (Figures 2D and 2E). Since these assays were done in
serum-free media, preventing proliferation (see Experimental
Procedures), the accelerated wound closure could not be due
to effects of ILEI on proliferation.
ILEI induces tumorigenicity and late steps
in metastasis formation
Next, we investigated whether stable ILEI expression would in-
duce tumor formation in normal, nontumorigenic EpH4 and
EpBcl-2 cells. We also asked whether ILEI would cause EMT
in vivo and enhanced tumor growth in EpC40 cells, which form
tumors but not metastases in nude mice (Janda et al., 2002a,
2002b). Accordingly, EpH4-ILEI, EpBcl-2-ILEI, and EpC40-ILEI
cells were injected into mammary gland fat pads of nude
mice, together with respective empty vector control cells.
EpH4-ILEI and EpBcl-2-ILEI cells induced small, slowly grow-
ing tumors in 8/10 and 4/6 mice, respectively (Figure 3A), while
the respective GFP control cells only formed tiny, rapidly re-
gressing nodules consisting of normal epithelial cells (data not
shown; Oft et al., 1996). Interestingly, the GFP+ tumor cells
from EpH4-ILEI lacked E-cadherin but expressed vimentin,
showing that the cells undergo EMT in vivo (Figure 3B). Reculti-
vated, GFP-positive tumor cells obtained by sorting retained
their ‘‘reversible EMT’’ phenotype on plastic (Figure 3C; com-
pare to Figure S1A).
Analysis of tumor formation by EpC40-ILEI cells and control
EpC40 cells revealed that ILEI strongly enhanced tumor size
(3.6-fold increase in mean tumor weight per mouse; Figure 3A).
To analyze whether ILEI induced EMT in these tumors, we com-
pared EpC40 and EpC40-ILEI tumors by immunohistochemistry
(IHC), staining serial tumor sections for E-cadherin, vimentin,
and ILEI expression. As expected (Janda et al., 2002a),
EpC40-derived tumors showed strong, membrane-localized E-
cadherin expression, while vimentin staining was predominantly
detected in the E-cadherin/ILEI-negative areas presumably rep-
resenting stroma (dashed lines, Figure 3D). In contrast, the ILEI-
positive cells in the EpC40-ILEI tumors showed no or weak cyto-
plasmic E-cadherin staining but strong vimentin expression
(Figure 3E). Interestingly, ILEI was restricted to cytoplasmic ves-
icles in the (nonmetastatic, epithelial) EpC40 cells but showed
enhanced cytoplasmic expression in the EMT-prone, metastatic
EpC40-ILEI cells (Figures 3D and 3E, bottom insets).
Importantly, the cells in both tumor types showed comparable
proliferation rates, as analyzed by KI67 staining (Figures S3A
and S3B). Thus, ILEI might enhance tumor growth by facilitating
local invasion as a consequence of EMT, rather than by acceler-
ating cell proliferation. The ability of ILEI to induce tumors was
not restricted to epithelial cells, since stable ILEI expression
also induced tumor formation in nontumorigenic 3T3 fibroblasts
(Figures S3C–S3E) and NMuMG mammary epithelial cells (A.G.,
K.H. Heider, and H.B., unpublished data).229
A R T I C L EFigure 2. Overexpressed exogenous ILEI causes EMT and migration in EpH4-derived cells
A and B: EpH4 cells (A) and EpRas cells (B) overexpressing retrovirally transduced ILEI (EpH4-ILEI, EpRas-ILEI) or empty GFP vector (EpH4, EpRas) were analyzed
on plastic, porous supports and in collagen gels for EMT by phase contrast micrography and immunofluorescence for E-cadherin and vimentin expression (see
Experimental Procedures).
C: Lysates from the EpH4-derived cells indicated, expressing or not expressing ILEI, were analyzed for E-cadherin, vimentin, and phospho-Erk/total Erk expres-
sion by Western blot, verifying ILEI overexpression by using anti-ILEI antibodies (top panels). Loading control, Smad2–3 antibodies (bottom panels).
Dand E: EpC40-ILEI and control EpC40 cells (EpC40-GFP) were analyzed for migratory activity in a wounding assay on plastic (see Experimental Procedures) by
photography 72 hr after wounding; (D; red dotted lines) and quantification of wound closure (E).
F: EpH4-ILEI and EpC40-ILEI cells were cultivated in collagen gels for 5 days, treated with 10 mM Ras inhibitor L739749 for another 5 days, and photographed
(representative data from one of three independent experiments). EpRas control cells treated similarly showed no evidence of inhibitor toxicity (right panels).
Scale bars in A–D and F, 100 mM.230 CANCER CELL SEPTEMBER 2006
A R T I C L EFigure 3. Overexpressed exogenous ILEI causes
tumor formation and EMT in vivo
A: ILEI-overexpressing EpH4, Ep-Bcl2, and EpC40
cells plus respective control cells were injected
into the mammary gland fat pads of nude
mice (50.000 cells per injection site, four injection
sites per mouse). Numbers of mice positive for
palpable tumors (top) and mean values 6 SD
of total tumor weights per mouse (bottom; *p <
0.05, significant difference) are shown.
B: Frozen sections of EpH4-ILEI- and EpC40-ILEI-
induced tumors (inset in E) were analyzed for
E-cadherin or vimentin expression by immuno-
fluorescence (rhodamine; red) in GFP+ donor
cells (FITC; green).
C: Reversible EMT (see Figure S1A) of >90% GFP+
tumor cells derived from EpH4-ILEI tumors on
plastic is depicted at low and high density, re-
spectively.
D and E: Serial paraffin sections from EpC40-ILEI-
induced tumors (E) and EpC40-GFP control tu-
mors (D) were stained by IHC with antibodies to
E-cadherin (top), vimentin (middle), and ILEI
(bottom). Note EMT induction and shift from ve-
sicular to cytoplasmic ILEI staining (large red in-
sets, bottom panels) in the EpC40-ILEI-induced
tumors. Black dotted lines in D, stromal areas (vi-
mentin-positive, E-cadherin- and ILEI-negative).
Blue insets in D and E: nonimmune IgG controls.
Scale bars in B–E, 100 mM.Since cells from the EpH4/EpRas model essentially fail to me-
tastasize directly from primary tumors, their metastatic ability
was analyzed by tail vein injection, allowing us to demonstrate
that EMT is a faithful in vitro correlate of late steps in metastasis
(see Huber et al., 2005). Accordingly, EpH4-ILEI, EpBcl-2-ILEI,
and EpC40-ILEI cells were tested for metastatic behavior by
tail vein injection of nude mice, in comparison to respective con-
trol cells. EpH4-ILEI and EpBcl-2-ILEI cells induced lung metas-
tases in w70% of the injected mice, the latter developing in-
creased numbers of much larger metastases (Figures 4A and
4B). In line with this, ILEI expression also induced strong meta-
static capacity in the tumorigenic but nonmetastatic EpC40 cells
(Figures 4A and 4B; 100% of mice, large metastases). Immuno-
histochemical staining of EpBcl-2-ILEI-induced metastases re-
vealed cytoplasmatic ILEI expression, weak E-cadherin staining,
and distinct vimentin expression (Figure 4C). Thus, stable ILEI
expression can enable normal EpH4 cells and nontumorigenic
EpBcl-2 cells to cause tumors and late steps in metastasis.
Recombinant ILEI protein can induce EMT in EpH4
and EpRas cells
To study whether extracellularly added ILEI protein could induce
similar readouts in EpH4 and EpRas cells as stable ILEICANCER CELL SEPTEMBER 2006overexpression, we tried to express and affinity purify recombi-
nant ILEI. Although several preparations of purified, biologically
active ILEI could be obtained (see Figures S2A and S2B), a
reproducible procedure to generate large amounts of recombi-
nant ILEI with high and stable bioactivity remains to be
developed.
Recombinant ILEI added to EpH4 or EpRas cells in collagen
gels was able to induce complete EMT, as shown by formation
of unordered structures consisting of migratory cells that ex-
pressed vimentin and lacked E-cadherin, while a control prepa-
ration did not (Figures S2C and S2D). Interestingly, recombinant
ILEI but not the control preparation also caused EMT in polar-
ized epithelial tubules pregrown in collagen gels in the absence
of ILEI (Figure S2E). As shown by time-lapse cinematography,
recombinant ILEI also induced motility of EpH4 cells grown on
plastic (Figure S2C and data not shown). For preliminary exper-
iments suggesting that neutralizing ILEI antibodies might pre-
vent EMT, see the Discussion and Figure S2F.
ILEI knockdown by RNAi in EpRasXT cells reverses EMT
and prevents metastasis
We next investigated if endogenous ILEI is necessary for EMT
and metastatic ability, also to rule out that the observed effects231
A R T I C L EFigure 4. Stable ILEI overexpression confers metastatic ability
A: Metastatic ability of nonmetastatic EpH4, Ep-Bcl2, and EpC40 cells upon ILEI overexpression was tested in nude mice by tail vein injection (5 3 105 cells/
mouse). Incidence (top) and mean numbers of lung metastases (bottom, mean 6 SD; *p < 0.05, significant difference) are shown.
B: Micrographs of sections from lung metastases induced by the above cell types as compared to lungs from control animals (EpH4-injected) are shown after
standard HE staining.
C: Analysis of EpBcl-2-ILEI-induced metastases by serial sectioning and IHC staining shows cytoplasmic ILEI staining (left panel), weak cytoplasmic E-cadherin
staining (right panel), and presence of vimentin (blue inset corresponding to area boxed in red in right panel). Left inset: control IgG staining.
Scale bars in B and C, 100 mM.of stable, exogenous ILEI expression represent overexpression
artifacts. Transient and stable RNA interference (RNAi) were em-
ployed to specifically reduce ILEI protein expression in EpRas
cells and EpRasXT cells, respectively. First, EpRasXT cells
were infected with retroviruses (Paddison et al., 2002) express-
ing two different ILEI-sh-RNAs (‘‘A’’ and ‘‘B’’) or luciferase-
sh-RNA as a control, together with red fluorescent protein (RFP)
to allow sorting of infected cells (see Experimental Procedures).
Using both ILEI constructs, strongly RFP-positive mass cultures
and clones could be expanded, in which secreted ILEI protein was
strongly reduced, as determined by Western blot (EpRasXT +
siRNA-ILEI; Figure 5A). On plastic, these cells had regained
epithelial morphology and membrane-localized E-cadherin ex-
pression but showed absent or strongly reduced vimentin ex-
pression, as detected by immunofluorescence (Figure 5B) and
Western blot (Figure 5A). In contrast, EMT was not affected in
control cells (Figure 5B; EpRasXT + siRNA-Luci). A similar rever-
sion of EMT in EpRasXT cells by ILEI-RNAi was obtained in col-
lagen gels (Figure 5C, left panels). Since ILEI probably functions
as an extracellular, secreted protein, recombinant ILEI should
reinduce EMT in the epithelial EpRasXT + siRNA-ILEI cells. Ad-
dition of recombinant ILEI to these cells in collagen gels indeed
reinduced EMT, while a mock preparation had no such effects
(Figure 5C). These findings confirm the specificity of the ILEI
knockdown by RNAi.
Transient transfection with a pool of four different siRNA oligo-
nucleotides against ILEI—or Luciferase as a control—was used
to determine whether ILEI is required for TGFb-mediated EMT232induction in EpRas cells. Strong or even complete knockdown
of ILEI protein expression was observed between 2 and 7
days after transfection. Accordingly, ILEI-siRNA-transfected
cells seeded into collagen gels failed to become migratory or
lose plasma membrane E-cadherin expression in response to
TGFb, while the control oligo-transfected cells became migra-
tory and spindle shaped, showing strongly reduced, often cyto-
plasmic E-cadherin expression (Figure 5D and data not shown).
Finally, we analyzed EpRasXT clones showing stable rever-
sion of EMT by retroviral ILEI-RNAi for tumorigenicity and meta-
static ability in nude mice, using EpRasXT + siRNA-Luci cells as
a control. Knockdown of ILEI still allowed tumor growth (Fig-
ure 5E) but strongly inhibited metastasis formation by EpRasXT
cells, since EpRasXT + siRNA-ILEI cells induced either no me-
tastases or a few tiny metastases after tail vein injection (Figures
5F and 5G).
ILEI can induce EMT independently of TGFb signaling
So far, our results did not exclude the possibility that ILEI acted
through TGFb, either by induction of TGFb secretion or by cross-
talk to the TGFb receptor. Consequently, knockdown of ILEI
might abolish autocrine TGFb production in EpRasXT cells—
shown earlier to cause slow reversal of EMT (Oft et al., 1996).
To test whether ILEI induces TGFb secretion, supernatants
from EpH4 and EpRas cells expressing or not expressing exog-
enous ILEI were analyzed in TGFb-ELISA assays. Secreted
TGFb was not detectably upregulated in EpH4-ILEI or EpRas-
ILEI cells, as compared to EpH4/EpRas control cellsCANCER CELL SEPTEMBER 2006
A R T I C L EFigure 5. Endogenous ILEI is necessary for EMT
and late steps of metastasis
A: Mass cultures (MC) and clones (C) of EpRasXT
cells stably expressing two different, retrovirally
transduced ILEI-specific siRNAs (‘‘A’’ and ‘‘B’’)
or a Luciferase (Luci)-specific control siRNA
were analyzed for ILEI and E-cadherin expression
in Western blots. Loading control, b-actin expres-
sion.
B andC: Phase micrographs and immunofluores-
cence analysis for E-cadherin and vimentin are
shown for siRNA-ILEI- or siRNA-Luci-expressing
EpRasXT clones on plastic (B) or in collagen gels
(C); see legend to Figure 2.
D: EpRas cells transiently transfected (days 0–2)
with Smart siRNA pools (Dharmacon) against
ILEI or Luciferase (Luci) were analyzed for ILEI ex-
pression 6 days after transfection (WB, left
panels) or cultured in collagen gels plus or minus
TGFb for 4 days (days 2–6), stained for E-cadherin
by immunofluorescence, and photographed
(middle and right panels). Insets: bright-field
photographs of gel structures (lumina, red dot-
ted lines).
E and F: EpRasXT-siRNA-ILEI and control clones
(see Aand B) were analyzed for tumor formation
(E; NS, not significant) and metastatic capacity
(F; *p < 0.05, significant difference) in nude
mice as described for Figures 3 and 4.
G: Histological analysis of lung metastases from
mice injected with EpRasXT-siRNA-ILEI and
EpRasXT-siRNA-Luci cells.
Scale bars in B–D and G, 100 mm.(Figure 6A). We then added high doses (5 ng/ml) of TGFb to ep-
ithelial EpRasXT-siRNA-ILEI cells, using EpRasXT + siRNA-Luci
cells as positive controls. As expected, TGFb readily induced
EMT in the control cells but failed to do so in the EpRasXT cells
in which ILEI was knocked down (Figure 6B). Thus, exogenous
TGFb seems to require enhanced ILEI expression in order to in-
duce EMT, raising the possibility that TGFbmight induce ILEI ex-
pression. Indeed, addition of TGFb to EpH4 and EpRas cells
clearly enhanced both intracellular and secreted ILEI protein
levels in these cells (Figure 6C).
We then addressed whether or not ILEI-induced EMT would
require signaling through the TGFb receptor, using the specific
TGFb-RI kinase inhibitor SB 431.542 (Inman et al., 2002). This in-
hibitor prevented TGFb-induced EMT in EpRas cells (Figure 6D,
top panels) but did not detectably interfere with EMT induction
by recombinant ILEI in the same EpRas cells (Figure 6D, bottom
panels). In conclusion, ILEI may represent an essential and im-
portant downstream effector of TGFb during EMT induction.CANCER CELL SEPTEMBER 2006Delocalized ILEI expression in human carcinomas
is associated with EMT, metastasis formation,
and poor prognosis
Finally, we asked whether ILEI expression was induced, en-
hanced, or altered in human carcinomas as compared to re-
spective normal epithelia. Since measuring ILEI mRNA levels
appeared to be meaningless due to translational control of
ILEI expression, we analyzed ILEI protein expression in sections
of human normal and tumor tissues by IHC, using ILEI peptide
antibodies (see Experimental Procedures). Many epithelial tis-
sues were negative (e.g., larynx, bladder, uterus, stomach, pros-
tate, lung; Figure 7C and data not shown). Other—predomi-
nantly secretory—epithelia (e.g., salivary gland, pancreas,
colon, duodenum, mammary gland) showed ILEI expression re-
stricted to small dot-like structures apical of the nucleus (which
could represent storage vesicles or Golgi-like structures; Fig-
ures 7A and 7B, green arrowheads). Except isolated positive
cells of possibly hematopoietic origin (Figures 7A–7C; red233
A R T I C L EFigure 6. ILEI acts independently of TGFb signal-
ing but may be a downstream effector
A:Concentrated supernatants from EpH4/EpRas
cells and their counterparts expressing exoge-
nous ILEI were tested for TGFb secretion in TGFb-
ELISA assays (see Experimental Procedures; error
bars; mean 6 SD from three experiments).
B: siRNA-ILEI- or siRNA-LUCI-expressing EpRasXT
cells (see Figure 5) were exposed to 5 ng/ml
TGFb in collagen gels and analyzed for morphol-
ogy and E-cadherin or vimentin expression by
immunofluorescence.
C: EpH4 and EpRas cells were treated (+) or not
treated (2) with 5 ng TGFb for 24 hr, and both
cell lysates and supernatants were analyzed for
ILEI expression by Western blot (asterisk indicates
background band).
D: EpRas cells seeded in collagen gels treated
(1.2 mg/ml, bottom panels) or not treated (top
panels) with recombinant ILEI in the absence or
presence of TGFb and/or TGFbRI inhibitor (SB
431542; 5 mM).
Scale bars in B and D, 100 mm.arrows) in the interstitial mesenchyme of these epithelia, con-
nective tissues, endothelia as well as smooth and striated mus-
cle were negative, as were neuronal tissues with the exception
of Purkinje cells (data not shown).
Interestingly, staining of various human carcinomas showed
enhanced cytoplasmic ILEI expression, sometimes in addition
to vesicle staining (Figures 7D–7H). In many tumor types (e.g.,
breast, colon, prostate, lung, liver, head, and neck) variable per-
centages of cases (13 to >50%) showed this strong ILEI staining
(Figure 7I and data not shown). Tumors induced by human car-
cinoma cell lines in mouse xenograft assays showed a similar
enhanced staining for ILEI (Figure S3F). To determine whether
strong cytoplasmic ILEI expression is associated with EMT in
human tumors, we employed the recent finding that epithelial
cells in the invasion front of human colon carcinomas undergo
transient EMT. These migratory cells show loss of E-cadherin,
induction of vimentin, and nuclear b-catenin expression (re-
viewed in Brabletz et al., 2005). While epithelial tumor cells in
the primary colon carcinoma (detected by basal cytokeratin
staining) show cytoplasmic b-catenin and granular staining for
ILEI (Figures S4A–S4C, middle panels), cells in the invasion front
combined nuclear b-catenin expression with strong cytoplasmic
ILEI staining (Figures S4A–S4C, bottom panels). Thus, cytoplas-
mic ILEI expression correlates with EMT and metastasis (see
also Figures 3E, 3F, and 4C).
Finally, we evaluated ILEI staining patterns in a human breast
cancer array containing tissue samples from 56 breast cancer234patients with known case histories covering up to 15 years, in
comparison to normal mammary gland. As expected, both mu-
rine and human mammary gland tissue showed ILEI expression
in granules apical of the nucleus (Figures 8A and 8B). In mam-
mary carcinomas, some tumors retained granular ILEI staining,
while others showed cytoplasmic staining (Figure 8C, red insets
of left and right panels, respectively). ILEI staining data from 43
patients were then correlated with the frequency of metastasis-
free and overall survival in Kaplan-Meyer plots. Cytoplasmic ILEI
expression was clearly correlated with a huge, statistically highly
significant decrease in metastasis-free and overall survival
(Figure 8D, Kaplan-Meyer plots; see Discussion). Interestingly,
KI67 staining of tumors with cytoplasmic ILEI expression
showed unchanged or reduced proliferation rates in comparison
to tumors with granular ILEI expression (Figure 8C, blue insets)
For definitions and details, see the Supplemental Experimental
Procedures.
Discussion
In this paper, we identify and functionally characterize ILEI as
a key player in both EMT and late-stage carcinoma progression.
ILEI is a member of a group of secreted proteins with largely un-
known function (FAM3A-D; Pilipenko et al., 2004; Zhu et al.,
2002). Polysome bound mRNA expression profiling (Pradet-
Balade et al., 2001) was instrumental to the identification of ILEI,
since expression of this gene was exclusively controlled at theCANCER CELL SEPTEMBER 2006
A R T I C L Elevel of translation (Figure 1B). This might also explain why ILEI
was not identified earlier by total mRNA expression profiling
studies (van ’t Veer et al., 2002).
Exogenous ILEI expression: Sufficient for EMT, tumor
formation, and metastasis?
Stable expression of ILEI in various EpH4-derived cells was suf-
ficient to induce EMT, (slow) tumor growth, and lung metastasis
upon subcutanous and intravenous injection, respectively (Fig-
ures 2–4). Thus, in the EpH4 system, ILEI is able to cause EMT
and tumor progression on its own. Oncogenic Ras alone only
modifies epithelial polarity in EpH4 cells (plastic epithelium)
but causes EMT-related phenotypes in other epithelial cell lines
(reviewed in Gru¨nert et al., 2003). Similarly, the E-cadherin re-
pressor Snail induces cell cycle arrest and apoptosis in EpH4
cells (M.J. and H.B., unpublished data) but causes EMT and en-
hanced metastatic ability in several human carcinoma cell lines
(Batlle et al., 2000). Other EMT-specific genes (PDGF-R signal-
ing genes, NF-kB, cellular regulator of E1A-regulated genes
Figure 7. Enhanced and delocalized expression of LEI protein in human
tumors
ILEI protein expression and localization in normal human tissues (A–C, mam-
mary tissue; see Figures 8A and 8B) or colon (D and E, colorectal AC) and
mammary carcinomas (F, IDC-G2; H, IDC-G3, G, AC) as analyzed by IHC
staining. Green arrowheads, granular staining of epithelial cells; red arrows,
single stained cells in interstitial mesenchyme. I:Abnormal ILEI expression de-
tected by IHC in various types of human carcinomas (compare A and D).
AC, adenocarcinoma; IDC, invasive ductal carcinoma; ILC, infiltrating lob-
ular carcinoma; SCC, small cell carcinoma; BAC, benign adenocarcinoma;
n.r., nonrelevant (low case numbers). Scale bars in A–H, 50 mM.CANCER CELL SEPTEMBER 2006[CREG], and the thrombin receptor PAR-1; Jechlinger et al.,
2003) induced EMT-like phenotypes in EpRas but not EpH4 cells
(Huber et al., 2004; Jechlinger et al., 2006; and data not shown).
Likewise, the Wnt/b-catenin, Notch, and hedgehog signaling
pathways induced EMT induction and tumor progression
when cooperating with other oncogenic events but sometimes
acted as tumor suppressors on their own (reviewed in Huber
et al., 2005). To some extent, ILEI function is mirrored by the
transcription factor Twist, sufficient for EMT induction in polar-
ized human mammary epithelial cells and necessary for metas-
tasis in murine mammary carcinoma cell lines (Yang et al., 2004).
Due to the limitations of the EpH4/EpRas model—metastasis
formation upon tail vein injection but no metastasis from ortho-
topic primary tumor sites—we can only conclude that ILEI is suf-
ficient for late steps in metastasis such as extravasation, inva-
sion, and proliferation of tumor cells at distant sites. Clearly,
EMT itself seems to be necessary but not sufficient for metasta-
sis, since weakly metastatic cells and their highly metastatic var-
iants can both exhibit EMT (reviewed in Huber et al., 2005).
Based on encouraging results from pilot experiments (data not
shown), we are currently investigating stable ILEI knockdown
in CT26 cells (Figure 1A), which metastasize from orthotopic
tumor sites (Oft et al., 1998) and show enhanced ILEI secretion
(Figure 1D).
It needs to be mentioned that EMT induced by ILEI alone is re-
versible on plastic and porous supports at high cell density
(Figure S1A), in contrast to EMT induced by Ras plus TGFb.
We speculate that ILEI-induced loss of epithelial polarity might
be reversed if the adherent cells in dense 2D cultures are forced
to undergo cell-cell contacts. This reestablishment of epithelial
polarity would then block ILEI function by preventing access
of apically secreted ILEI to the (basolaterally expressed) ILEI re-
ceptors. In collagen gels, EpH4-ILEI cells can maintain stable
EMT, since cell-cell adhesion is not enforced by adhesion to
plastic. The fact that EpRas and EpS35 cells express N-Cad-
herin (A. von Bredow and H.B., unpublished data) and thus
exhibit more ‘‘plastic’’ epithelial contacts might also explain
why ILEI can cause stable EMT of these cells in 2D cultures
(Figure S1B).
Endogenous ILEI is necessary for EMT, tumor formation,
and metastasis and acts downstream
of TGFb receptor signaling
Endogenous ILEI expression, which is upregulated in EpRas
cells after EMT (EpRasXT cells), is necessary for EMT and tumor
progression, as demonstrated by transient and stable knock-
down of ILEI via RNAi in EpRas and EpRasXT cells, respectively
(Figure 5). This ruled out the possibility that the observations
made with exogenously expressed ILEI were artifacts due to
nonphysiological expression levels. The stable ILEI knockdown
was specific for ILEI, since recombinant ILEI (Figure S2) rein-
duced EMT in epithelial EpRasXT-siRNA-ILEI cells (Figure 5C).
First results with neutralizing ILEI antibodies also suggest that
endogenous, secreted ILEI can cause EMT via an autocrine
loop (Figure S2F). Our finding that ILEI acts independently of
TGFb signaling and downstream of TGFb function (Figure 6) ex-
cludes the (somewhat trivial) possibility that ILEI employs TGFb
secretion or TGFb-R signaling to induce EMT. Mouse tumors in-
duced by EpRas cells initially undergo EMT in vivo in response to
stromal TGFb (Oft et al., 1996). Thus, TGFb produced by the tu-
mor stroma might induce ILEI both in the tumor cells and in the235
A R T I C L EFigure 8. ILEI expression in human breast cancer: Strong cytoplasmic ILEI expression correlates with increased metastasis and decreased survival
A and B: A human breast cancer tissue array derived from 56 patients with known case histories, containing 71 tumor (T) or lymph node metastasis (Lnm; L)
tissue samples was analyzed for intracellular distribution of ILEI by IHC. Normal murine (A) and human mammary gland tissue (B; N; adjacent to T34 or L 59) show
granular ILEI expression.
C: ILEI staining of tumors T44, T45, and T31 (from patients without metastasis) and T9, T30, and Lnm L14 (from patients with two or more types of metastases),
yielding granular and cytoplasmic ILEI staining, respectively (red insets). Intensities of ILEI staining (0–6) and proliferation rates of these tumors as analyzed by
KI67 antibody staining (blue insets) are also indicated.
D: Intracellular ILEI distribution (seeC) was analyzed in all available tumor samples and correlated in Kaplan-Meyer plots to metastasis-free survival (top panel)
and overall survival (bottom panel). Vertical ticks, censored patients. For definitions of these terms and further details, see the Supplemental Experimental
Procedures.
Scale bars in A–C, 50 mM.stromal cells itself, thus contributing to tumor progression in
a dual fashion (see below).
How does ILEI function in altering epithelial plasticity?
Since analysis of ILEI-dependent signal transduction or identi-
fication of the receptor has to await mass production of bioac-
tive ILEI (see the Supplemental Experimental Procedures), little
is known about its mechanisms of action. Interestingly, expres-
sion profiling of ILEI-expressing EpH4 and EpRas cells revealed
ILEI-induced upregulation of multiple chemokines, cytokines,
growth factor receptors, and cytoplasmic signaling intermedi-
ates (T.W. and H.B., unpublished data). In addition, preliminary
data suggest that ILEI expression strongly induced upregula-
tion of the PDGF receptor (PDGFRa and b; W. Mikulits and
H.B., unpublished data), which is required in an autocrine
PDGF/PDGFR loop for murine and human tumor progression
(Jechlinger et al., 2006). This suggests that ILEI might be an in-
ducer of multiple autocrine growth factor and chemokine loops,
raising the question of whether ILEI-dependent signaling path-
ways that are necessary for ILEI function are induced via these236secondary autocrine loops or directly via the unknown ILEI re-
ceptor. Examples for such pathways are the observed acti-
vation of the Erk/MAPK pathway in EpH4 and EpC40 cells
(Figure 2C) and the requirement of Ras function for ILEI-in-
duced EMT (Figure 2F). Since EMT induction by ILEI readily oc-
curs only in collagen gels (where extensive biochemical analy-
sis is difficult; Janda et al., 2002b), biochemical studies on ILEI
function will be a challenge even when recombinant ILEI is
available.
Does ILEI also function in other cellular systems? Stable ILEI
expression causes epithelial plasticity changes and/or tumor
formation in NMuMG mammary epithelial cells (A.G., K.H.
Heider, and H.B., unpublished data) or hepatocytes (W. Mikulits
and H.B., unpublished data). Furthermore, ILEI renders 3T3 cells
tumorigenic (Figure S3). Finally, siRNA-mediated knockdown of
human ILEI in the dedifferentiated, invasive human mammary
carcinoma cell line CAMA-I interfered with its EMT phenotype
(Figure S5A) in a fashion similar to that observed for PDGF-R
tyrosine kinase inhibitors (Jechlinger et al., 2006). This shows
that ILEI is also important in human tumor cells.CANCER CELL SEPTEMBER 2006
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carcinomas?
Expression of endogenous ILEI in human tumors and normal tis-
sues had to be measured at the protein level, since this gene is
translationally regulated and ubiquitously expressed at the
mRNA level (Zhu et al., 2002). This also explained why respec-
tive analyses using the GeneLogic database (Dolznig et al.,
2005) did not reveal significant upregulation of ILEI mRNA in hu-
man tumors. In both normal tissues and certain tumors, ILEI pro-
tein was localized to dot-like, suprabasal structures that could
represent Golgi structures or storage vesicles (Figures 7A, 7B,
and 8A–8C). In many other tumors, however, enhanced, often
cytoplasmic staining for ILEI was observed (Figures 7D–7H
and 8C). Interestingly, this cytoplasmic staining was also ob-
served in tumor cells undergoing EMT at the invasion front of co-
lon carcinomas (Figure S4), suggested to represent migratory
tumor stem cells (Brabletz et al., 2005). Furthermore, cytoplas-
mic ILEI staining was strongly correlated with a shortened me-
tastasis-free and overall survival in human breast cancer pa-
tients (Figure 8D). Importantly, cytoplasmic ILEI staining did
not correlate with multiple other clinical markers for a bad prog-
nosis in breast cancer, with the possible exception of HER2 pro-
tein expression (Table S1). This suggests that ILEI can serve as
an independent prognostic marker in breast cancer.
How could vesicular versus cytoplasmic localization of ILEI
have an impact on tumor cell invasiveness? We speculate that
granular IHC staining indicates vesicular storage of ILEI protein
in normal and benign tumor cells that do not secrete ILEI except
in response to specific stimuli. In line with this, polysome bound
ILEI mRNA levels correlated with secreted but not total ILEI pro-
tein levels. This points to strict control of ILEI secretion in normal
cells, which might be altered or lost during EMT or cancer pro-
gression, leading to autocrine secretion plus reuptake of ILEI
into endocytic vesicles, which would appear as cytoplasmic
staining at the low resolution of IHC. Similar results have been
obtained for deposition of the EMT-specific ECM protein Tenas-
cin C, which is likewise translationally controlled (Jechlinger
et al., 2003).
Interestingly, single small cells localized in the interstitial mes-
enchyme of normal epithelia also showed strong ILEI staining,
most likely representing hematopoietic cells, which were some-
times massively increased in carcinomas. In chronic inflamma-
tory tissue (e.g., collagen-induced rheumatoid arthritis in rat
paws), macrophages, mast cells, and lymphocytes were
strongly ILEI positive (IHC; T.W. and H.B., unpublished data).
During tumorigenesis, ILEI might thus be produced initially by
chronic inflammatory cells (Coussens and Werb, 2002), favoring
epithelial plasticity, migration, EMT, and autocrine production of
ILEI during tumor cell progression/dedifferentiation. Once po-
tent neutralizing anti-ILEI antibodies are available, these will
be tested for their ability to interfere with tumor growth and/or
local invasion of human tumor cells in mouse xenografts, helping
to decide whether ILEI might be a promising target for thera-
peutic, humanized antibodies to combat breast carcinoma
progression.
Experimental procedures
Cells and culture conditions
The origin, culture conditions, and analysis of epithelial/mesenchymal
markers in EpH4 mouse mammary epithelial cells and derivatives (forCANCER CELL SEPTEMBER 2006a detailed description, see the Supplemental Experimental Procedures)
have been described earlier (Janda et al., 2002a; Oft et al., 1998). The breast
ductal carcinoma cell line MDA-MB-435, the human epidermoid carcinoma
line A431, and NIH 3T3 fibroblasts were purchased from ATCC (Manassas,
VA).
EpH4/EpRas cells expressing retrovirally transduced ILEI cells were culti-
vated in F12/DMEM (Gibco) plus 10% fetal calf serum (FCS) and 20% condi-
tioned medium (from confluent cultures, added every 48 hr). Three-dimen-
sional collagen gel cultures of EpH4 cells and their derivatives were
performed as described earlier (Janda et al., 2002a; Oft et al., 1996), and
0.1%–0.5% FCS was added for the first 2 days of culture.
Identification of ILEI as an EMT/metastasis-specific, translationally
controlled gene
Gene expression profiling of polysome bound mRNA from the EpH4- and
CT26-derived cell lines mentioned above (see Figure 1A) and identification
of EMT-specific genes (including ILEI) by cluster analysis were performed
as described earlier (Jechlinger et al., 2003). After cloning and sequencing
of the full-length ILEI c-DNA, further searching of the database identified
ILEI as a member (FAM3C; accession number AAR84605) of a little-charac-
terized gene family (FAM3; Zhu et al., 2002).
Determination of total and polysome bound ILEI mRNA
by semiquantitative RT-PCR
Polysomal bound mRNA of EpRas and EpRASXT cells was isolated by
sucrose gradient fractionation (Jechlinger et al., 2003) and mRNA isolation
using RNeasy Mini Kit (Qiagen). One-tube RT-PCR was performed as de-
scribed by the supplier (Titan, Roche Inc.) Either 15 (total RNA) or 19 PCR
cycles (polysomal RNA) were performed to quantify ILEI mRNA, using b-actin
as a loading control. For primers used, see the Supplemental Data.
Stable cell lines expressing retrovirally transduced ILEI and
ILEI-siRNA
The ILEI coding sequence (see Zhu et al., 2002) was PCR amplified using
Gateway (Invitrogen)-compatible primers (see the Supplemental Data). Ret-
roviral producer cell lines (NIH-3T3 gp + 86 cells) were transfected with the
retroviral construct pMSCV-IRES-GFP; (Moriggl et al., 1999) using Fugene
(Roche). Supernatants from FACS-sorted, strongly GFP+ producer cells
were used to infect EpH4 derivatives and NIH3T3 cells. Cells were FACS
sorted twice for stable GFP expression, generating mass cultures (>80%
GFP+) or single cell clones. V5-tagged ILEI was generated by inserting the
ILEI coding sequence into the modified pDEST 47 vector (Invitrogen) and
used to transfect Cos 7 cells with Fugene 6 (Roche) according to the manu-
facturer’s protocols.
Two different oligos encoding ILEI sh-RNAs (‘‘A’’ and ‘‘B’’; for sequences,
see the Supplemental Data) were inserted into the vector pSHAG according
to protocols from Gregory Hannon (CSH laboratories, NY) and transferred to
the Gateway modified pMSCV-IRES-RFP vector (Clontech). Retroviral infec-
tion and selection of RFP-expressing cells were performed as described
above. ILEI expression of all cell lines generated was determined by Western
blot analysis. For transient knockdown of ILEI in EpRas cells, a Smart siRNA
pool coding for four different ILEI regions (Dharmacon Inc.) was transfected
with Dharmacon buffer 2 using 10 ng of siRNA according to the manufac-
turer’s instructions. As a control, scrambled oligos (Dharmacon) were used
similarly (for sequences, see the Supplemental Data). ILEI levels were mon-
itored by Western blot 2–7 days after transfection. Two days after transfec-
tion, cells were seeded into collagen gels and treated or not treated with
TGFb (Janda et al., 2002a).
Antibodies
Antibodies to ILEI were generated by immunization of rabbits (Gramsch Lab-
oratories) with a KLH-coupled ILEI peptide or purified, full-length ILEI protein.
For IHC, antibodies to crossreacting FAM3 family members were absorbed
prior to IHC using peptides from FAM3A and FAM3D and used at 300 ng/
ml for IHC and 15 ng/ml for Western blot analysis. For origin, preparation, de-
scription, and dilutions of all antibodies used for IHC, immunofluorescence,
Western blots, or functional assays in this paper, see the Supplemental
Experimental Procedures.237
A R T I C L EImmunofluorescence and IHC
Antibody staining of cells for immunofluorescence, performed on plastic
(glass chamber slides; Nunc), on filter culture inserts (pore size 0.4 mm, Bec-
ton Dickinson), or in whole collagen gel structures was performed as de-
scribed earlier (Janda et al., 2002a; Oft et al., 1996). Fluorescent staining
for GFP, RFP, E-cadherin, and vimentin was visualized by conventional or
confocal fluorescence microscopy (Axiovert 200M, Zeiss), using DAPI
(Roche) for DNA counterstaining.
For IHC, the staining unit ‘‘Discovery’’ (Ventana Medical systems) was
used according to the manufacturer’s instructions (for details, see the Sup-
plemental Experimental Procedures).
Western blot analysis
All cell lysates were prepared and subjected to Western blot analysis as de-
scribed earlier (Janda et al., 2002a); for antibodies see above. Lysates from
cells with stable ILEI expression were prepared from cells cultivated for 24 hr
with less than 30% final confluency. To determine secreted ILEI protein
levels, 1 3 106 cells were cultured on a 10 cm dish (NUNC) in 10 ml of se-
rum-containing media for 18 hr, washed three times, and cultivated for 18
hr in 7 ml of serum-free media (DMEM + 0.1% BSA). Cleared supernatants
were concentrated 5- to 7-fold by vacuum drying and analyzed in Western
blots, after normalization to cell numbers. Total protein content was deter-
mined from cell pellets (Bradford assay, BioRad Inc.).
Quantification of TGFb1 by ELISA
Cell culture supernatants of EpH4 derivatives (33 105 cells, 35 mm dishes, 1
ml of serum-free medium, 5-fold concentration) were normalized as above
(WB ILEI). They were analyzed for total secreted TGFb1 by the TGFb1
Emax Immuno Assay System (Promega, Madison), according to the manu-
facturer’s instructions, and independently determined by a contract labora-
tory (Perbio Science GmbH, Germany).
Phenotypical analysis of EpH4-derived cells stably expressing ILEI
ILEI-expressing and control EpH4 cells and derivatives (see Figure 1A) were
analyzed on plastic and porous supports (using both sparse [<20% conflu-
ent] and dense [50%–80% confluent] cultures) and collagen gels for mor-
phology, E-cadherin, and vimentin as described earlier (Janda et al.,
2002a; Oft et al., 1996). For wound closure assay, a wound (w2 mm) was
scratched into confluent cultures (10 cm dish, Nunc) of GFP- or ILEI-express-
ing EpH4 or EpC40 cells, which were preincubated with serum-free DMEM
for 24 hr, and cultivated in serum-free DMEM containing glutamine (Gibco),
0.2% BSA, and human transferrin. Wound regions with an identical width
were marked, and wound closure (percentage of closed scratch area) was
measured in photographs of 15 randomly selected wound areas at the
time points indicated.
Experimental tumor and metastasis assay
Tumor formation and metastatic ability of EpH4 cells and derivatives were
determined by mammary gland fat pad or tail vein intravenous injection
into 6- to 9-week-old BalbC athymic nude mice (nu/nu, Charles River
Wega GmbH, Germany; Janda et al., 2002a), according to IMP-held animal
experiment approvals from the Austrian Bundesministerium fu¨r Bildung, Wis-
senschaft und Kultur. After determination of tumor weight and/or photogra-
phy, excised tumors and metastatic lungs were fixed with paraformaldehyde
(4%, 18 hr, 4C) and post fixed (70% ethanol, 16 hr) before dehydration and
paraffin embedding. For frozen sections, fixed tissues were incubated in
HEPES-buffered 20% sucrose (18 hr), embedded Tissue-Tek (Lab-Tek Prod-
ucts, Miles Lab.), and frozen (240C). Paraffin sections were stained with he-
matoxylin/eosin according to standard protocols or subjected to IHC stain-
ing. Lung metastasis was quantified by counting metastatic lesions in 50
sections (w0.3 mm apart, representing about 50% of lung volume). Data
(corrected for large metastatic lesions spanning more than one section)
were expressed as average numbers of metastases from ten sections. For
recultivation of cells from ILEI-induced mouse tumors, tumor tissues were
dissociated as described elsewhere (Janda et al., 2002a). Tumor cells were
expanded (media plus 30 mg/ml ciprofloxacin; Roche), and mass cultures
(>90% GFP-positive cell populations) were selected by repeatedly FACS
cell sorting.238Human normal and carcinoma tissues
The following paraffin-embedded human normal or tumor tissues were
employed: prostate cancer array (no. CC 19-01-003), lung cancer array
T8235724-5 (BioCat, Heidelberg, Germany), diverse human normal and can-
cer tissues (Oridis Biomed, Graz, Austria), and colon carcinomas (T.B.). A
large breast cancer array (MS) was analyzed retrospectively by IHC staining,
according to protocols approved by the institutional review board of the
Medical University of Vienna (see the Supplemental Experimental Proce-
dures).
Supplemental data
The Supplemental Data include Supplemental Experimental Procedures, five
figures, and one table and can be found with this article online at http://www.
cancercell.org/cgi/content/full/10/3/227/DC1/.
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